Too much visceral fat can lead to cardio metabolic disease

Some new research has been done on the weight loss medication Acomplia and it was seen that the drug can significantly reduce levels of human visceral fat. This type of fat is the most dangerous fat that collects around the stomach. The research that was done in Japan shows that Acomplia can reduce what is known as metabolically active fat, which tends to collect around vital human organs like the liver and the pancreas.

The study results that were announced at the AGM of the EU Association for the Study of Diabetes explained that the researchers had looked at both types of fat in the body namely visceral fat and subcutaneous fat. Too much visceral fat can lead to cardio metabolic disease, insulin resistance and type 2 diabetes.

The researchers looked at over 500 obese men and women who participated in the study. They saw that the volunteers who were given a regular dose of Acomplia ended up with a much lower amount of visceral fat when compared to those volunteers who were given the placebo drug.

Sanofi Aventis are very keen to prove that Acomplia is not just simply a weight loss aid but also a drug that can help with metabolism complications such as diabetes. If they can do this then they are far more likely to get state approval for the drug to be used in hospitals and it will also shed the image of Acomplia being a lifestyle pill as opposed to a serious medication.

Acomplia is a novel weight loss drug in that it works on brain receptors to control the appetite. It has been on sale in the United Kingdom for over a year now and has been selling well. Most European countries also sell Acomplia with a prescription from a doctor. The Food and Drug Administration in America has yet to give approval for Acomplia to be sold there.